US4440758A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Poly-cation salts of bis(or tris)[4-O-monohexose-oxy]-arylene sulfate derivatives
Assignee: Wyeth Holdings LLC
•
Filing: 1982-10-25
•
Granted: 1984-04-03
•
Expires: 2002-10-25
Abstract
Abstract Poly-cation salts of bis(or tris)[4-O-monohexose-oxy]-arylene sulfate derivatives useful as modulators of the complement system, the intermediates thereof and the process of making such intermediates and products.
Inventors
- 👤 Janis Upeslacis
- 👤 Robert E. Schaub
- 👤 Seymour Bernstein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 19:48
CPC Classifications
C; C07; C07H; C07H15/00; C07H15/20; C07H15/203
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
106 words
A compound selected from those of the formula: ##STR5## wherein X is --SO 3 M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia, zinc and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); B is selected from the group consisting of --NHCO-- and --NHSO 2 --; n is an integer 2 or 3; and Z is an arylene selected from the group consisting of: ##STR6##
Claim 2
Dependent Claim
106 words
A compound selected from those of the formula: ##STR5## wherein X is --SO 3 M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia, zinc and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); B is selected from the group consisting of --NHCO-- and --NHSO 2 --; n is an integer 2 or 3; and Z is an arylene selected from the group consisting of: ##STR6##
Claim 3
Dependent Claim
25 words
The compound according to claim 1, dodecatriethylammonium N,N',N"-tris[4-[(2,3,4,6-tetra-O-sulfo-β-D-glucopyranosyl)oxy]phenyl]-1,3,5-benzenetrisulfonamide, where the structure is: ##STR7## wherein A is N + H(C 2 H 5 ) 3 .
Claim 4
Dependent Claim
13 words
The compound according to claim 1, dodecasodium N,N',N"-tris[4-[(2,3,4,6-tetra-O-sulfo-β-D-glucopyranosyl)oxy]phenyl]-1,3,5-benzenetrisulfonamide, where the structure is: ##STR8##
Claim 5
Dependent Claim
55 words
A compound selected from those of the formula: ##STR9## wherein Y is selected from the group consisting of H and --COCH 3 ; B is selected from the group consisting of --NHCO-- and --NHSO 2 --; n is an integer 2 or 3; and Z is an arylene selected from the group consisting of: ##STR10##
Claim 6
Dependent Claim
55 words
A compound selected from those of the formula: ##STR9## wherein Y is selected from the group consisting of H and --COCH 3 ; B is selected from the group consisting of --NHCO-- and --NHSO 2 --; n is an integer 2 or 3; and Z is an arylene selected from the group consisting of: ##STR10##
Claim 7
Dependent Claim
18 words
The compound according to claim 4, N,N',N"-tris[4-[(2,3,4,6-tetra-O-acetyl-β-D-glycopyranosyl)oxy]phenyl]-1,3,5-benzenetrisulfonamide, where the structure is: ##STR11## wherein Y is --COCH 3 .
Claim 8
Dependent Claim
12 words
The compound according to claim 4, N,N',N"-tris[4-[(β-D-glucopyranosyl)oxy]phenyl]-1,3,5-benzenetrisulfonamide, where the structure is: ##STR12##
Claim 9
Independent Claim
135 words
A method of modulating the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement modulating amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR13## wherein X is --SO 3 M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia, zinc and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); B is selected from the group consisting of --NHCO-- and --NHSO 2 --; n is an integer 2 or 3; and Z is an arylene selected from the group consisting of: ##STR14##
Claim 10
Independent Claim
135 words
A method of modulating the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement modulating amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR13## wherein X is --SO 3 M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia, zinc and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); B is selected from the group consisting of --NHCO-- and --NHSO 2 --; n is an integer 2 or 3; and Z is an arylene selected from the group consisting of: ##STR14##
Claim 11
Dependent Claim
13 words
The method according to claim 7, wherein the body fluid is blood serum.
Claim 12
Dependent Claim
12 words
The method according to claim 7, wherein the compound is dodecatriethylammonium N,N',N"-tris[4-[(2,3,4,6-tetra-O-sulfo-β-D-glucopyranosyl)oxy]phenyl]-1,3,5-benzenetrisulfonamide.
Claim 13
Dependent Claim
12 words
The method according to claim 7, wherein the compound is dodecasodium N,N',N"-tris[4-[(2,3,4,6-tetra-O-sulfo-β-D-glucopyranosyl)oxy]phenyl]-1,3,5-benzenetrisulfonamide.
Claim 14
Independent Claim
132 words
A method of modulating the complement system in a warm-blooded animal which comprises administering to said warm-blooded animal an effective complement modulating amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR15## wherein X is --SO 3 M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia, zinc and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); B is selected from the group consisting of --NHCO-- and --NHSO 2 ; n is an integer 2 or 3; and Z is an arylene selected from the group consisting of: ##STR16##
Claim 15
Independent Claim
132 words
A method of modulating the complement system in a warm-blooded animal which comprises administering to said warm-blooded animal an effective complement modulating amount of a pharmaceutically acceptable compound selected from those of the formula: ##STR15## wherein X is --SO 3 M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia, zinc and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ); B is selected from the group consisting of --NHCO-- and --NHSO 2 ; n is an integer 2 or 3; and Z is an arylene selected from the group consisting of: ##STR16##
Claim 16
Dependent Claim
12 words
The method according to claim 11, wherein the compound is dodecatriethylammonium N,N',N"-tris[4-[(2,3,4,6-tetra-O-sulfo-β-D-glucopyranosyl)oxy]phenyl]-1,3,5-benzenetrisulfonamide.
Claim 17
Dependent Claim
12 words
The method according to claim 11, wherein the compound is dodecasodium N,N',N"-tris[4-[(2,3,4,6-tetra-O-sulfo-β-D-glucopyranosyl)oxy]phenyl]-1,3,5-benzenetrisulfonamide.
Claim 18
Dependent Claim
12 words
The method according to claim 11, wherein the compound is administered internally.
Claim 19
Dependent Claim
12 words
The method according to claim 11, wherein the compound is administered topically.
Claim 20
Dependent Claim
16 words
The method according to claim 11, wherein the compound is administered periodontally in the oral cavity.
Claim 21
Dependent Claim
12 words
The method according to claim 11, wherein the compound is administered intra-articularly.
Claim 22
Dependent Claim
12 words
The method according to claim 11, wherein the compound is administered parenterally.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-04-03 | 1987-10-03 | 1988-04-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-04-03 | 1991-10-03 | 1992-04-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-04-03 | 1995-10-03 | 1996-04-03 | $7700.00 | Window Closed / Lapsed |